Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma

Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma

Показать другие версии (1)

Severe asthma is responsible for considerable morbidity and a high proportion of the healthcare costs attributable to asthma. Management is not straightforward as the clinical, pathological and physiological features are heterogeneous and the relationships between these features are poorly understoo...

Полное описание

Библиографические подробности
Главные авторы:	Berair, R, Pavord, I
Формат:	Journal article
Язык:	English
Опубликовано:	2013

Схожие документы

Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.
по: Berair, R, и др.
Опубликовано: (2013)

Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
по: Shrimanker, R, и др.
Опубликовано: (2017)

Evidence for the efficacy and safety of anti- interleukin-5 treatment in the management of refractory eosinophilic asthma
по: Xue, L, и др.
Опубликовано: (2015)

Interleukin-5 in the Pathophysiology of Severe Asthma
по: Corrado Pelaia, и др.
Опубликовано: (2019-12-01)

Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma.
по: Desai, D, и др.
Опубликовано: (2013)

Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma
по: Bart Hilvering, и др.
Опубликовано: (2015-08-01)

Anti-interleukin-5 therapy in severe asthma
по: Gilles Garcia, и др.
Опубликовано: (2013-09-01)

Bronchial asthma and interleukin-5
по: Das Undurti, и др.
Опубликовано: (2001-02-01)

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD
по: Nora Drick, и др.
Опубликовано: (2022-10-01)

Emerging biologics in severe asthma
по: Pavord, I, и др.
Опубликовано: (2016)

Mepolizumab, quality of life, and severe eosinophilic asthma.
по: Pavord, I
Опубликовано: (2017)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
по: Pelaia C, и др.
Опубликовано: (2017-10-01)

Possible Role for Interleukin-5 in Asthma
по: Yacoob Y. Al-Rubaeyi, и др.
Опубликовано: (2007-01-01)

Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma
по: Trivedi, A, и др.
Опубликовано: (2016)

Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity
по: Fatemeh Saheb Sharif-Askari, и др.
Опубликовано: (2021-07-01)

Controversies in allergy: should severe asthma with eosinophilic phenotype always be treated with anti-IL-5 therapies
по: Pavord, I, и др.
Опубликовано: (2019)

Targeted deletion of Interleukin-3 results in asthma exacerbations
по: Julia Kölle, и др.
Опубликовано: (2022-06-01)

Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial
по: Lina Brinkmann, и др.
Опубликовано: (2024-11-01)

Influence of anti-interleukin (IL)-5/anti-IL-5 receptor-α treatment on work productivity in patients with severe eosinophilic asthma
по: Nora Drick, и др.
Опубликовано: (2023-05-01)

Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register
по: Marianne Baastrup Soendergaard, и др.
Опубликовано: (2022-10-01)

Bronchial thermoplasty for the treatment of asthma.
по: Martin, N, и др.
Опубликовано: (2009)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
по: Howell, I, и др.
Опубликовано: (2024)

Mepolizumab treatment in patients with severe eosinophilic asthma.
по: Ortega, H, и др.
Опубликовано: (2014)

Articular manifestations related to anti-interleukin-5 therapies in severe asthma: a case series
по: Clairelyne Dupin, и др.
Опубликовано: (2024-02-01)

Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study
по: Laura Mattei, и др.
Опубликовано: (2021-10-01)

Treatment of severe covid-19 with interleukin 6 receptor inhibition
по: Stephen Burgess, и др.
Опубликовано: (2022-12-01)

Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
по: Florence Roufosse
Опубликовано: (2018-04-01)

Biomarkers for severe eosinophilic asthma.
по: Yancey, S, и др.
Опубликовано: (2017)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
по: Gunsoy, N, и др.
Опубликовано: (2017)

Is the neutrophil the key effector cell in severe asthma?
по: Kamath, A, и др.
Опубликовано: (2005)

Th2 cytokines and asthma — Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists
по: Borish Larry, и др.
Опубликовано: (2001-02-01)

Role of interleukin-4 receptor α polymorphism in patients with asthma and its correlation with asthma severity
по: Nidhi Girdhar, и др.
Опубликовано: (2025-01-01)

Will I get addicted to my asthma treatment?
по: Pavord, I, и др.
Опубликовано: (1991)

Role of Interleukin 5 Inhibition in the Treatment of Eosinophilic Otitis Media
по: Nathaniel K. Breslin, и др.
Опубликовано: (2021-02-01)

How I do it: workup of severe asthma
по: Couillard, S, и др.
Опубликовано: (2021)

Interleukin-4 (C590T) Gene Polymorphism in Association with Asthma Severity
по: Al-Ahmad M, и др.
Опубликовано: (2023-11-01)

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
по: Diego Bagnasco, и др.
Опубликовано: (2017-08-01)

Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma.
по: Brightling, C, и др.
Опубликовано: (2003)

Noneosinophilic asthma: a distinct clinical and pathologic phenotype.
по: Haldar, P, и др.
Опубликовано: (2007)

Evidence for interleukin-5 in nasal polyps in aspirin-induced asthma
по: Norihisa Ogata, и др.
Опубликовано: (1997-01-01)